



Documenting Use of Lipid Therapy for CAD

Outlines the proper workflow for documenting the use of lipid therapy for Coronary Artery Disease (CAD)


Purpose of Structured Data

- Documenting the use of lipid therapy for coronary artery disease (CAD) is a Uniform Data System (UDS) measure

Description of Measure

- This measure looks at the total percentage of patients 18 years of age and older who have an active diagnosis of CAD, were diagnosed as having had a myocardial infarction (MI), or had cardiac surgery in the past and were prescribed a lipid-lowering therapy

Workflow – Overview



Workflow - Detail

1. Verify the patient falls into one of the following three categories:
 - a. Active diagnosis of Coronary Artery Disease (CAD)
 - b. History of Myocardial Infarction (MI)
 - c. History of Cardiac Surgery
2. If the patient falls into either of the above categories and has no current medication then you would proceed with prescribing a new medication, when appropriate unless the patient falls under one of the two exclusion criteria:
 - a. Individuals whose last low-density lipoprotein (LDL) lab test during the measurement year was less than 130 mg/dL
 - b. Individuals with an allergy to or a history of adverse outcomes from or intolerance to LDL lowering medications
3. To prescribe new med, select the Medications icon 
4. Click the **Prescribed** Meds button to prescribe a medication. Utilizing the **CAD Lipid Therapy (UDS)** medication picklist, select a medication for the patient, when appropriate
5. Add and/or edit the desired sig details, refills, frequency, dispense amount, etc. and click **Save**
6. On the **Medication Summary** screen or the **Overview** tab select to eRx or Print the medication



7. You may also call in the medication by phone or fax the medication. However, if the prescription is called in or faxed, you must update the method column to display accordingly after the med has been added/updated for the selected encounter



Note: Patients that are receiving a form of treatment other than pharmacologic treatment, are involved in therapeutic lifestyle changes, and/or control of non-lipid risk factors without concomitant pharmaceutical treatment are considered non-compliant for this measure